Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage  

作　　者：Ping Xue Li-Hui Deng Qing xia Zhao-Da Zhang Wei-Ming Hu Xiao-Nan Yang Bing Song Zong-Wen Huang 

机构地区：[1]Department of Integrated Traditional Chinese and Western Medicine, West China ~Iospital, Sichuan University,Chengdu 610041, Sichuan Province, China [2]Department of General Surgery,West China Hospital, Siciauan University, Chengdu 610~)4i,Sichuan Province, China [3]Department of Radiology, West China Hospital,Sichuan University, Chengdu 610041, Sichuan Province, China

出　　处：《World Journal of Gastroenterology》2008年第3期474-478,共5页世界胃肠病学杂志（英文版）

摘　　要：AIM:To evaluate the therapeutic effect of alanyl- glutamine dipeptide (AGD) in the treatment of severe acute pancreatitis (SAP) in early and advanced stage. METHODS: Eighty patients with SAP were randomized and received 100 mL/d of 20% AGD intravenously for 10 d starting either on the day of (early treatment group) or 5 d after (late treatment group) admission. Groups had similar demographics, underlying diseases, Ranson score, Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score, and Balthazar’s computed tomography (CT) score at the beginning of the study and underwent similar other medical and nutritional management. RESULTS: The duration of acute respiratory distress syndrome (2.7 ± 3.3 d vs 12.7 ± 21.0 d, P < 0.01), renal failure (1.3 ± 0.5 d vs 5.3 ± 7.3 d, P < 0.01), acute hepatitis (3.2 ± 2.3 d vs 7.0 ± 7.1 d, P < 0.01), shock (1.7 ± 0.4 d vs 4.8 ± 3.1 d, P < 0.05), encephalopathy (2.3 ± 1.9 d vs 9.5 ± 11.0 d, P < 0.01) and enteroparalysis (2.2 ± 1.4 d vs 3.5 ± 2.2 d, P < 0.01) and hospital stay (28.8 ± 9.4 d vs 45.2 ± 27.1 d, P < 0.01) were shorter in the early treatment group than in the late treatment group. The 15-d APACHE Ⅱ score was lower in the early treatment group than in the late treatment group (5.0 ± 2.4 vs 8.6 ± 3.6, P < 0.01). The infection rate (7.9% vs 26.3%, P < 0.05), operation rate (13.2% vs 34.2%, P < 0.05) and mortality (5.3% vs 21.1%, P < 0.05) in the early treatment group were lower than in the late treatment group.CONCLUSION: Early treatment with AGD achieved a better clinical outcome in SAP patients.AIM： TO evaluate the therapeutic effect of alanyl-glutamine dipeptide （AGD） in the treatment of severe acute pancreatitis （SAP） in early and advanced stage. METHODS： Eighty patients with SAP were randomized and received 100 mL/d of 20% AGD intravenously for 10 d starting either on the day of （early treatment group） or 5 d after （late treatment group） admission. Groups had similar demographics, underlying diseases, Ranson score, Acute Physiology and Chronic Health Evaluation Ⅱ （APACHE Ⅱ） score, and Balthazar＇s computed tomography （CT） score at the beginning of the study and underwent similar other medical and nutritional management. RESULTS： The duration of acute respiratory distress syndrome （2.7±3.3d vs 12.7±21.0d, P 〈 0.01）, renal failure （1.3±0.5 d vs 5.3±7.3 d, P 〈 0.01）, acute hepatitis （3.2±2.3 d vs 7.0 ±7.1 d, P 〈 0.01）, shock （1.7±0.4 d vs 4.8±3.1 d, P 〈 0.05）, encephalopathy （2.3±1.9 d vs 9.5±11.0 d, P 〈 0.01） and enteroparalysis （2.2±1.4 d vs 3.5±2.2 d, P 〈 0.01） and hospital stay （28.8±9.4 d vs 45.2±27.1 d, P 〈 0.01） were shorter in the early treatment group than in the late treatment group. The 15-d APACHE Ⅱ score was lower in the early treatment group than in the late treatment group （5.0±2.4 vs 8.6±3.6, P 〈 0.01）. The infection rate （7.9% vs 26.3%, P 〈 0.05）, operation rate （13.2% vs 34.2%, P 〈 0.05） and mortality （5.3% vs 21.1%, P 〈 0.05） in the early treatment group were lower than in the late treatment group.CONCLUSION： Early treatment with AGD achieved a better clinical outcome in SAP patients.

关 键 词：Severe acute pancreatitis Alanyl-glutaminedipeptide Clinical study 

分 类 号：R576[医药卫生—消化系统]